Oxford Nanopore rises on strong 2025 revenue growth

Oxford Nanopore said 2025 revenue will be £223m–£224m (up ~22% reported, ~24% at constant currency versus £183.2m in 2024), nudging past prior guidance and lifting the stock c.8% to 152p. Growth was broad-based: Clinical +~60%, BioPharma +30%, Applied Industrial +27%, Research +15%, with PromethION product line >40% y/y growth. The company ended 2025 with roughly £302m in cash and liquid investments, citing improved working capital and balance-sheet strength; full preliminary results and an investor webcast are scheduled for 2 March 2026.

Analysis

Market structure: Oxford Nanopore (LSE:ONT) is a clear near-term winner—broad-based +24% constant-currency revenue and PromethION >40% growth signal accelerating adoption among large-scale users (hospitals, biopharma, industrial). Winners include consumables suppliers and high-throughput genomics centers; losers are incumbent short-read vendors that face share pressure in high-throughput, long-read niches (partial headwind to Illumina). The strength implies tighter short‑term demand for flow cells/consumables and improving recurring revenue visibility, enhancing ONT’s pricing power for enterprise installations.

Risk assessment: Tail risks include regulatory/clinical validation setbacks, a major data-accuracy or product-quality recall, or a sudden cut in biopharma R&D budgets; any of these could erase gains quickly. Immediate (days) risk is a volatility pullback around investor Q&A; short-term (weeks/months) hinge on 2 Mar prelims and large order disclosures; long-term depends on sustaining consumables attach rates and conversion of PromethION installations into recurring revenue. Hidden dependencies: attach-rate dynamics, single large-customer concentration, and FX translation given ~24% growth at constant currency.

Trade implications: Implement directional and relative-value trades: buy ONT to play accelerating clinical & PromethION adoption while hedging exposure to legacy short-read winners. Options can amplify asymmetric upside into the Mar 2 event—buy call spreads to cap premium. Sector rotation: overweight diagnostics/consumables (TMO) and underweight academic-centric instrument names (PACB) where funding headwinds persist.

Contrarian angles: The market may underweight the durability of clinical revenue (60% YoY could be lumpy) and overrate immediate margin expansion—watch gross-margin progression, not just revenue. Conversely, the move may be underdone if ONT converts more enterprise customers; historical parallel: Illumina’s early read‑length battles show small vendors can win niche share then scale. Unintended consequence: aggressive price competition on flow cells could compress future margins even amid top-line growth.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Oxford Nanopore (LSE:ONT) at market up to 160p ahead of the 2 Mar prelims; target 220p within 3 months (~+45%) with a hard stop at 120p (-21%).
• Construct a dollar‑neutral relative‑value trade: long ONT (1.5% portfolio) vs short Illumina (NASDAQ:ILMN) (1.5%) for 3–6 months to capture sequencing share rotation; trim if ONT >+30% or ILMN <-15%.
• Buy a 6–12 week call spread on ONT (e.g., buy 150p / sell 230p) sized to risk 0.5–1% of portfolio to leverage the Mar 2 catalyst while capping premium outlay; close on hit of 220p or at expiry.
• Reduce exposure to academic‑focused sequencing names (e.g., PacBio NASDAQ:PACB) by ~40% over the next 4 weeks and redeploy into diagnostics/consumables winners (e.g., Thermo Fisher NYSE:TMO) or into the ONT positions above.